Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from <scp>DAPA</scp> ‐ <scp>CKD</scp> and <scp>FIGARO</scp> ‐ <scp>DKD</scp>
Diabetes, Obesity and Metabolism, 2025
de la Rambelje M., Voors A., Greasley P., Berger M., Heerspink H.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
CVD Nephrology | Pathophysiology | Plasma |  Olink Explore 3072/384 |
Abstract
No abstract, letter format article.